Clinical research results for Kelun-Biotech's TROP2 ADC sacituzumab tirumotecan (sac-TMT) published in Nature Medicine, a top international medical journal
Results
TNBC: Based on the results of the multicenter, randomized, controlled Phase III OptiTROP-Breast01 (NCT05347134) clinical study, the current publication reports on the efficacy and safety of sac-TMT versus investigator's choice chemotherapy for the treatment of patients with locally advanced, recurrent or metastatic TNBC. The results of the study showed that sac-TMT demonstrated statistically and clinically significant improvements in both progression-free survival (PFS) and overall survival (OS) compared to investigator's choice chemotherapy. Based on this study, sac-TMT was approved for marketing for the treatment of adult patients with unresectable locally advanced or metastatic TNBC who have received at least two prior systemic therapies (at least one of them for advanced or metastatic setting). The data from this study were presented in an oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
NSCLC: Based on the results of two early clinical studies of sac-TMT, the article reports on the efficacy and safety of sac-TMT in previously treated advanced NSCLC with or without epidermal growth factor receptor (EGFR) mutations. The article also explored in vitro experiments on the potential mechanisms of sac-TMT treatment for NSCLC, suggesting that EGFR mutations can increase the endocytosis and anti-tumor activity of TROP2 ADCs.
Dr. Michael Ge, CEO of Kelun-Biotech said, 'These successful publications in Nature Medicine mark the international academic community's recognition of the clinical efficacy and application value of sac-TMT in the treatment of advanced TNBC and NSCLC. The Company's novel product, sac-TMT, has been marketed in China for two indications. Meanwhile, the Company is also actively promoting the registrational clinical studies of sac-TMT in multiple indications, including breast cancer and lung cancer. Kelun-Biotech has always been committed to promoting innovation and leadership, and we look forward to continuing our research in the field of ADCs in partnership with MSD.'
About sac-TMT (佳泰莱®)
Sac-TMT, a core product of the Company, is a novel human TROP2 ADC in which the Company has proprietary intellectual property rights, targeting advanced solid tumors such as NSCLC, breast cancer (BC), gastric cancer (GC), gynecological tumors, among others. Sac-TMT is developed with a novel linker to conjugate the payload, a belotecan-derivative topoisomerase I inhibitor with a drug-to-antibody-ratio (DAR) of 7.4. Sac-TMT specifically recognizes TROP2 on the surface of tumor cells by recombinant anti-TROP2 humanized monoclonal antibodies, which is then endocytosed by tumor cells and releases KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable, it can enable a bystander effect, or in other words kill adjacent tumor cells.
In May 2022, the Company licensed the exclusive rights to MSD (the tradename of Merck & Co., Inc., Rahway, NJ, USA) to develop, use, manufacture and commercialize sac-TMT in all territories outside of Greater China (includes Mainland China, Hong Kong, Macau, and Taiwan).
To date, two indications for sac-TMT have been approved and marketed in China for the treatment of adult patients with unresectable locally advanced or metastatic TNBC who have received at least two prior systemic therapies (at least one of them for advanced or metastatic setting) and EGFR mutation-positive locally advanced or metastatic non-squamous NSCLC following progression on EGFR-TKI therapy and platinum-based chemotherapy. Sac-TMT became the first domestic ADC with global intellectual property rights to be fully approved for marketing. It is also the world's first TROP2 ADC to be approved for marketing in a lung cancer indication. In addition, the NDA application for sac-TMT for the treatment of adult patients with EGFR-mutant locally advanced or metastatic NSCLC who progressed after treatment with EGFR-TKI therapy was accepted by the NMPA, and was included in the priority review and approval process. As of today, Kelun-Biotech has initiated 8 registrational clinical studies in China. MSD has initiated 12 ongoing Phase 3 global clinical studies of sac-TMT as a monotherapy or with pembrolizumab or other agents for several types of cancer. These studies are sponsored and led by MSD.
About Kelun-Biotech
Kelun-Biotech（6990.HK）is a holding subsidiary of Kelun Pharmaceutical (002422.SZ), which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. The company focuses on major disease areas such as solid tumors, autoimmune, inflammatory, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. The Company is committed to becoming a leading global enterprise in the field of innovative drugs. At present, the Company has more than 30 ongoing key innovative drug projects, of which 3 projects have been approved for marketing, 1 project is in the NDA stage, and more than 10 projects are in the clinical stage. The company has established one of the world's leading proprietary ADC platforms, OptiDC™, and has 1 ADC project approved for marketing, 1 ADC project in NDA stage, and multiple ADC or novel ADC projects in clinical or preclinical research stage. For more information, please visit https://kelun-biotech.com/.
View original content to download multimedia: https://www.prnewswire.com/news-releases/clinical-research-results-for-kelun-biotechs-trop2-adc-sacituzumab-tirumotecan-sac-tmt-published-in-nature-medicine-a-top-international-medical-journal-302426984.html
SOURCE Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Meyers Manx and Tuthill Debut the LFG at The Quail, A Motorsports Gathering
A new era in luxury off-road adventure, launching with six years of curated global driving experiences MONTEREY, Calif., Aug. 15, 2025 /PRNewswire/ -- At the prestigious The Quail, A Motorsports Gathering during Monterey Car Week, Meyers Manx, the legendary creator of the original fiberglass dune buggy, and world-renowned rally specialists Tuthill unveiled the LFG, a limited-production off-road performance machine set to redefine the spirit of recreational driving. Only 100 examples of the LFG will be built, each offering owners exclusive access to six years of meticulously planned driving adventures across the globe. The journey begins in 2027 with the inaugural LFG Baja Tour, marking the 50th anniversary of Meyers Manx's historic victory in the first Mexican 1000 (now the Baja 1000). Designed for those who crave both comfort and capability, the LFG merges cutting-edge engineering with a playful, adventurous spirit. Underneath its carbon fiber body and ROPS (Roll Over Protection Structure) lies a choice of high-performance engines — including a 4-valve variant derived from Tuthill's celebrated "K" — paired with a six-speed sequential gearbox and 4WD featuring front, center, and rear limited-slip differentials. Twin five-way adjustable dampers with hydraulic bump stops, and BF Goodrich All-Terrain tyres ensure the LFG is equally at home crossing desert dunes or carving through rugged mountain trails. Inside, a bespoke, climate-controlled cabin offers comfort on long hauls, while an Inconel exhaust, integrated GPS, and long-range fuel tank prepare the vehicle for journeys well beyond the beaten path. In moments, the enclosed cockpit can transform into an open-air buggy, letting drivers and passengers fully embrace the elements. "This project started as a dream between my long-time pal Richard and me, both in constant pursuit of the ultimate expression of freedom and performance," said Phillip Sarofim, Founder and CEO of Trousdale Ventures and Chairman of the Board at Meyers Manx. "We imagined the perfect Meyers Manx, brought Freeman Thomas on board to infuse his design brilliance, and merged it with Tuthill's engineering mastery. The result is raw, visceral, novel, and totally uncompromising. We call it LFG for a reason." "It's fairly well known that I love experiences, I love the effect it has on those that join us wherever we go," said Richard Tuthill, Director at Tuthill. "This, however, is slightly different. We are not necessarily bringing the stopwatch with us on these trips. I want to take people to see the most amazing parts of the world. I have been super lucky to see some life-changing scenery whilst Rallying, the memories I have as a result are immeasurable. These things change you. I think for the better. We crave experiences that we can look back on for the rest of our lives. We now have an amazing car to help us to create these in a unique way. The car looks fun, mischievous, it has a character that I have genuinely never seen or felt. BUT underneath it's PROPER – could we go to the moon and back in it? Probably yes, it has the capability to go wherever we point it, and we can do it safely and comfortably. In 2 minutes, it transforms from a fully air-conditioned enclosed cabin to a doorless buggy where the wind provides the air that helps us smile. It's very special. I can't wait to get started, please join in – LFG." More details, images, and specifications are available online. About Meyers ManxFounded in 1964 by Bruce Meyers, Meyers Manx is the creator of the original fiberglass dune buggy — an enduring symbol of freedom, adventure, and off-road performance. The brand blends innovation with heritage, inspiring generations of adventurers worldwide. Today, Meyers Manx continues to pioneer the future of recreational and off-road vehicles through a fusion of timeless design and modern engineering. Press Contactinfo@ About TuthillTuthill is a family-owned business based in Oxfordshire, UK, with over 50 years of success in rallying and racing. Known for building high-performance vehicles for both tarmac and off-road terrain, the company's legacy began with Francis Tuthill's participation in the 1977 London to Sydney Marathon. Now under second-generation leadership, Tuthill continues to deliver reliability, competitiveness, and desirability through motorsport and road car programs, including the acclaimed Tuthill K and GT ONE. Press ContactSales Inquiries: David Cox & Richard Tuthill — lfg@ | +44 (0) 1295 750 514Brand & Partnerships: Pia Jarak — pia@ Media Inquiries: Laura Harris — media@ View original content to download multimedia: SOURCE Meyers Manx Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 hours ago
- Yahoo
InventHelp Inventor Develops New Potty Training Accessory (SGM-538)
PITTSBURGH, Aug. 15, 2025 /PRNewswire/ -- "I wanted to create a product that would make potty training a less stressful and more positive experience for parents and children," said an inventor, from New Palestine, Ind., "so I invented THE POTTY PARTNER. My design could help provide a positive transition from diapers to toilet use, and it could allow for successful training in a shorter time or at an earlier age." The patent-pending invention provides an effective accessory for toilet training a child. In doing so, it would teach young children how to use the toilet in a positive and non-stressful manner. It also could help with safety issues. As a result, it could help simplify the task of toilet training. The invention features a durable and novel design that is easy to attach, use, and clean so it is ideal for parents with infants and children ages 3 and younger. Additionally, a prototype model and technical drawings are available upon request. The original design was submitted to the Indianapolis sales office of InventHelp. It is currently available for licensing or sale to manufacturers or marketers. For more information, write Dept. 24-SGM-538, InventHelp, 100 Beecham Drive, Suite 110, Pittsburgh, PA 15205-9801, or call (412) 288-1300 ext. 1368. Learn more about InventHelp's Invention Submission Services at View original content to download multimedia: SOURCE InventHelp Sign in to access your portfolio
Yahoo
5 hours ago
- Yahoo
Epigenetics Market worth US$4.29 billion in 2030 with 13.9% CAGR
DELRAY BEACH, Fla., Aug. 15, 2025 /PRNewswire/ -- The global Epigenetics Market, valued at US$2.03 billion in 2024, stood at US$2.24 billion in 2025 and is projected to advance at a resilient CAGR of 13.9% from 2025 to 2030, culminating in a forecasted valuation of US$4.29 billion by the end of the period. The major factors driving the growth in the flow cytometry market include advancements in technology, increasing adoption of flow cytometry products in clinical diagnostics, rising prevalence of chronic diseases, growing biopharmaceutical R&D, and the need for precision medicine. The significant rise in oncology research has increased the demand for flow cytometry products and services. Additionally, the integration of AI and machine learning is enhancing data analysis capabilities, further fueling market growth. Download PDF Brochure: Browse in-depth TOC on "Epigenetics Market" 365 - Tables45 - Figures353 - Pages By offering, the global epigenetics market is segmented into various categories, including kits and reagents, enzymes, instruments and accessories, software, and services. Within the kits and reagents category, there are sub-segments such as antibodies, chip-sequencing kits and reagents, bisulfite conversion kits and reagents, whole-genome amplification kits and reagents, 5-HMC and 5-MC analysis kits and reagents, histones, as well as other kits and reagents. In 2024, the Antibodies segment is projected to command the largest market share. This is attributed to the increasing reliance on antibodies for the detection, identification, and modification of proteins, along with their essential function in monitoring cellular regulation and gene expression. Consequently, the growth of the antibodies segment is expected to accelerate throughout the forecast period due to these advancements. By Method, the epigenetics market segmentation by methodology includes DNA methylation, histone modifications, and additional approaches such as non-coding RNA interactions and chromatin remodeling. The DNA methylation segment is projected to exhibit a robust compound annual growth rate (CAGR) throughout the forecast period, primarily driven by its proven effectiveness in oncology research applications. By geography, The Asia Pacific region is projected to experience the most rapid growth within the epigenetics market. This expansion is driven by the increasing global footprint of local companies through strategic alliances and collaborations, alongside continuous enhancements in healthcare infrastructure in emerging economies. Moreover, there is a heightened emphasis on advancing capabilities in Next-Generation Sequencing (NGS), which is further propelling market development in the region. Request Sample Pages : Key players in the epigenetics market include Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Illumina, Inc. (US), PacBio (US), Danaher (US), Active Motif, Inc. (US), Bio-Rad Laboratories, Inc. (US), Promega Corporation (US), Revvity (US), QIAGEN (Germany), among others. Illumina Inc (US): In 2024, Illumina, Inc. maintained a preeminent position in the genomics market, capitalizing on a well-established customer base that includes leading pharmaceutical and biotechnology companies, genomic research institutions, and various government laboratories and hospitals. The firm possesses a dominant market share in the next-generation sequencing (NGS) domain, which affords it a competitive edge when exploring adjacent sectors, such as epigenetic sequencing. A notable move in this direction occurred in June 2025, when Illumina announced its acquisition of SomaLogic. This strategic acquisition is poised to bolster Illumina's footprint in the burgeoning epigenetics market and further its multiomics strategy, integrating diverse biological data for enhanced insights into genomics, transcriptomics, proteomics, and epigenomics. Thermofisher Scientific Inc. (US) Thermo Fisher Scientific Inc. (US) stands out as a prominent player in the epigenetics market in 2024, driven by a robust and diversified product portfolio, an extensive global footprint, and a strategic focus on both organic and inorganic growth initiatives. Notably, in July 2025, the company secured US Food and Drug Administration (FDA) approval for the Oncomine Dx Express Test, utilizing the Ion Torrent Genexus Dx Integrated Sequencer as an in vitro diagnostic (IVD) assay designed for companion diagnostics (CDx) in tumor profiling applications. Thermo Fisher demonstrates a strong commitment to research and development, channeling significant resources into innovation to address the dynamic needs of its clientele. Their comprehensive global distribution network enhances accessibility and customer support, facilitating the delivery of advanced and reliable epigenetics solutions. This multifaceted strategic approach solidifies Thermo Fisher's position as a leading provider in the epigenetics landscape. For more information, Inquire Now! Related Reports: Research Antibodies & Reagents Market Genomics Market Next Generation Sequencing Market PCR Technologies Market Digital PCR and qPCR Market Get access to the latest updates on Epigenetics Companies and Epigenetics Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter, LinkedIn and Facebook. Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@ Our Website: Logo: View original content: SOURCE MarketsandMarkets Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
